Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Renal Medullary Carcinoma: Utility of [<sup>18</sup>F]FDG PET/CT in Evaluating Extent of Disease and Impact on Treatment Management.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Improve the Efficacy of B7-H3-Targeting Antibody-Drug Conjugate DS-7300a in TP53-deficient Tumors by Inducing Ferroptosis.

bioRxiv : the preprint server for biology·2026
Same author

[<sup>18</sup>F]DASA-23 PET/MRI evaluation in newly-diagnosed and recurrent high-grade glioma.

Neuroradiology·2026
Same author

Case Report: Management of a challenging case presenting with dysphagia after thyroidectomy requiring administration of liquid <sup>131</sup>I via MIC-KEY low-profile tube-a multidisciplinary approach.

Frontiers in medicine·2026
Same author

PSMA PET/CT-Derived Indicators and Outcomes After [<sup>177</sup>Lu]Lu-PSMA-617: A Multicenter Retrospective Analysis from the U.S. Expanded-Access Program.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration.

The Lancet. Oncology·2026

相关实验视频

Updated: Jun 19, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.8K

前列腺特异性膜抗原无线电配体治疗在患有侵袭性变异性前列腺癌的患者中.

Moein Moradpour1, Abuzar Moradi Tuchayi1, Surekha Yadav1

  • 1Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine
|March 5, 2026
PubMed
概括

与非AVPC患者相比,接受前列腺特异性膜抗原 (PSMA) 向放射性联体疗法 (RLT) 的侵袭性变异性前列腺癌 (AVPC) 患者表现出类似的PSA降低,但整体存活率更差. 这些发现表明,如果PSMA表达足够,PSMA RLT可能是AVPC的可行选择.

关键词:
AVPC AVPC AVPC AVPC AVPC AVPC AVPC AVPC AVPC AVPC AVPC AVPC AVPC AVPC AVPC AVPC AVPC AVPC AVPC AVPC AVPC AVPC AVPC AVPC AVPC AVPC AVPC AVPC AVPC AVPC AVPC AVPC AVPC AVPC AVPC在PSMA RLT上侵袭性变体前列腺癌是前列腺癌的一个变体.mCRPC 的使用情况.总体存活率 总体存活率

更多相关视频

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K
A New Technique for Treating Low-risk Prostate Cancer&#8212;Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

979

相关实验视频

Last Updated: Jun 19, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.8K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K
A New Technique for Treating Low-risk Prostate Cancer&#8212;Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

979

科学领域:

  • 在瘤学瘤学.
  • 核医学是一种核医学.
  • 泌尿生殖系统的癌症

背景情况:

  • 侵袭性前列腺癌 (AVPC) 具有高风险特征,通常用化疗治疗.
  • 前列腺特异性膜抗原 (PSMA) 向的放射性联体疗法 (RLT) 是一种新兴的治疗方法,用于转移性割抵抗性前列腺癌 (mCRPC).

研究的目的:

  • 评估使用PSMA RLT治疗AVPC患者的结局.
  • 为了比较AVPC患者的治疗反应和存活率与接受PSMA RLT的非AVPC患者.

主要方法:

  • 对82名AVPC患者和3个学术中心接受PSMA RLT的非AVPC患者的配对队列进行了回顾性研究.
  • AVPC患者被分为临床病理学 (AVPC-C) 和分子特征 (AVPC-MS) 组.
  • 分析了前列腺特异性抗原 (PSA) 反应,PSA无进展生存率 (PFS),总生存率 (OS) 和成像参数 (SUV平均值,总瘤体积).

主要成果:

  • 在AVPC (62.1%) 和非AVPC (60.7%) 组中,实现≥50%PSA降低的患者的百分比是相似的.
  • 中位数PSA PFS为AVPC的3.2个月,而非AVPC的4.2个月 (P=0.10).
  • 与非AVPC患者 (13.3个月) 相比,AVPC患者的中位寿命显著较短 (11.8个月) (P=0.04). 在AVPC-MS和AVPC-C亚组之间没有观察到显著的OS差异.

结论:

  • 与非AVPC患者相比,接受PSMA RLT治疗的AVPC患者的整体存活率明显降低.
  • 尽管OS较差,但AVPC患者的PSA应答率与PSMA RLT相似.
  • 对于具有足够PSMA表达的AVPC患者,应考虑PSMA RLT.